#Japan #Tokyo #GEM Premier 7000 #IL Japan #Hemolysis Detection

IL Japan Unveils the Innovative GEM Premier 7000 Blood Gas Analyzer

IL JAPAN Co., Ltd., headquartered in Minato, Tokyo, is making headlines with the announcement of its highly anticipated blood gas analyzer, the GEM Premier 7000. Set to hit the market on October 1, 2025, this state-of-the-art medical device promises significant advancements in the analysis of whole blood samples, particularly in accurately detecting hemolysis—an issue that can compromise the integrity of test results.

Introducing GEM Premier 7000

The GEM Premier 7000 serves as a crucial tool for medical institutions, enabling the rapid analysis of whole blood samples to assess key parameters such as acid-base balance, electrolyte levels, and metabolic byproducts. These parameters are essential for diagnosing the oxygenation capacity and overall physiological state of patients.

Key Features of GEM Premier 7000

1. Detection of Hemolysis in Whole Blood Samples
- The analyzer incorporates a quality assurance system known as iQM3, which employs advanced techniques akin to those used in conventional clinical laboratory devices to detect hemolysis. This capability is vital since hemolysis can drastically affect the concentration of potassium and other critical biomarkers, leading to potentially misleading test results.

2. Robust Quality Assurance System
- The iQM3 monitors reliability through a process that includes six comprehensive checks before, during, and after analysis, ensuring a continuous quality management system for all samples. This automation facilitates real-time error detection and necessary system corrections, streamlining the testing process and improving efficiency in clinical settings.

3. Automated Hemolysis Detection with GEM PAK Cartridge
- The GEM Premier 7000 is equipped with a GEM PAK cartridge designed for ease of use and safety. With all consumables integrated into one unit, the risks associated with biohazards are significantly reduced, allowing operators to focus on patient care. The cartridge maintains the necessary components for blood gas testing, simplifying the procedure and ensuring consistent results.

Development History and Background

The development of the GEM Premier 7000 stemmed from a decade-long collaboration with Lund University, Jenoptik, and AcouSort, precipitated by the growing need for reliable testing solutions in bedside and emergency clinical settings. The device aims to address the significant challenge posed by hemolysis, which is known to skew potassium readings, leading to mismanagement of patient care despite seemingly normal potassium levels.

Future Developments

IL Japan plans to progressively introduce the GEM Premier 7000 to key clinical areas such as emergency departments, operating rooms, ICU, and NICU worldwide. The company is committed to enhancing the quality of its offerings and support systems, ensuring they provide beneficial solutions to healthcare professionals and their patients.

About IL JAPAN Co., Ltd.

IL JAPAN is a subsidiary of the global leader in in vitro diagnostics and medical devices, Werfen, which specializes in acute care testing including blood coagulation tests and blood gas analysis. Established in 1966, Werfen operates in over 30 countries and has a presence in more than 100 regions through agents, showcasing an annual revenue exceeding €2.2 billion with around 7,000 employees.

Contact Information

For further inquiries, please reach out to:

• - Company: IL JAPAN Co., Ltd.
• - Blood Gas Business Unit Contact: Kiyoshi Tamura
• - Address: 1-3-30 Mita, Minato, Tokyo, 108-0073, Japan
• - Phone: +81-3-5419-1301
• - Email: [email protected]
• - Website: Werfen Japan

>Note: The details in this press release reflect information as of the publication date and may be subject to change without prior notice.